Skip to main content

Advertisement

SpringerLink
Log in

Utility of surrogate markers for the prediction of relapses in inflammatory bowel diseases

  • Review
  • Published:
Journal of Gastroenterology Aims and scope Submit manuscript

Abstract

Patients with diagnosed inflammatory bowel disease (IBD) will commonly experience a clinical relapse in spite of a prolonged therapy-induced period of clinical remission. The current methods of assessing subclinical levels of low-grade inflammation which predispose patients to relapse are not optimal when considering both cost and patient comfort. Over the past few decades, much investigation has discovered that proteins such as calprotectin that are released from inflammatory cells are capable of indicating disease activity. Along with C-reactive protein and erythrocyte sedimentation rate, calprotectin has now become part of the current methodology for assessing IBD activity. More recently, research has identified that other fecal and serum biomarkers such as lactoferrin, S100A12, GM-CSF autoantibodies, α1-antitrypsin, eosinophil-derived proteins, and cytokine concentrations have variable degrees of utility in monitoring gastrointestinal tract inflammation. In order to provide direction toward novel methods of predicting relapse in IBD, we provide an up-to-date review of these biomarkers and their potential utility in the prediction of clinical relapse, given their observed activities during various stages of clinical remission.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Fig. 1

Similar content being viewed by others

References

  1. Mao R, Xiao YL, Gao X, Chen BL, He Y, Yang L, et al. Fecal calprotectin in predicting relapse of inflammatory bowel diseases: a meta-analysis of prospective studies. Inflamm Bowel Dis. 2012;18(10):1894–9.

    Article  PubMed  Google Scholar 

  2. Wright EK, De Cruz P, Gearry R, Day AS, Kamm MA. Fecal biomarkers in the diagnosis and monitoring of Crohn’s disease. Inflamm Bowel Dis. 2014;20(9):1668–77.

    Article  PubMed  Google Scholar 

  3. Mowat C, Digby J, Strachan JA, Wilson R, Carey FA, Fraser CG, et al. Faecal haemoglobin and faecal calprotectin as indicators of bowel disease in patients presenting to primary care with bowel symptoms. Gut. 2015;pii:gutjnl-2015-309579. doi:10.1136/gutjnl-2015-309579.

  4. McDonald PJ, Digby J, Innes C, Strachan JA, Carey FA, Steele RJ, et al. Low faecal haemoglobin concentration potentially rules out significant colorectal disease. Colorectal Dis. 2013;15(3):e151–9.

    Article  CAS  PubMed  Google Scholar 

  5. Nakarai A, Kato J, Hiraoka S, Kuriyama M, Akita M, Hirakawa T, et al. Evaluation of mucosal healing of ulcerative colitis by a quantitative fecal immunochemical test. Am J Gastroenterol. 2013;108(1):83–9.

    Article  CAS  PubMed  Google Scholar 

  6. Mooiweer E, Fidder HH, Siersema PD, Laheij RJ, Oldenburg B. Fecal hemoglobin and calprotectin are equally effective in identifying patients with inflammatory bowel disease with active endoscopic inflammation. Inflamm Bowel Dis. 2014;20(2):307–14.

    Article  PubMed  Google Scholar 

  7. Takashima S, Kato J, Hiraoka S, Nakarai A, Takei D, Inokuchi T, et al. Evaluation of mucosal healing in ulcerative colitis by fecal calprotectin vs fecal immunochemical test. Am J Gastroenterol. 2015;110(6):873–80.

    Article  PubMed  Google Scholar 

  8. Kushner I. C-reactive protein and the acute-phase response. Hosp Pract (Off Ed). 1990;25(3A):13, 6, 21–8.

  9. Tall AR. C-reactive protein reassessed. N Engl J Med. 2004;350(14):1450–2.

    Article  CAS  PubMed  Google Scholar 

  10. Ballou SP, Kushner I. C-reactive protein and the acute phase response. Adv Intern Med. 1992;37:313–36.

    CAS  PubMed  Google Scholar 

  11. Saverymuttu SH, Hodgson HJ, Chadwick VS, Pepys MB. Differing acute phase responses in Crohn’s disease and ulcerative colitis. Gut. 1986;27(7):809–13.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  12. Pepys MB, Druguet M, Klass HJ, Dash AC, Mirjah DD, Petrie A. Immunological studies in inflammatory bowel disease. Ciba Found Symp. 1977;46:283–304.

    PubMed  Google Scholar 

  13. Beattie RM, Walker-Smith JA, Murch SH. Indications for investigation of chronic gastrointestinal symptoms. Arch Dis Child. 1995;73(4):354–5.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  14. Vermeire S, Van Assche G, Rutgeerts P. Laboratory markers in IBD: useful, magic, or unnecessary toys? Gut. 2006;55(3):426–31.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  15. Andre C, Descos L, Vignal J, Gillon J. C-reactive protein as a predictor of relapse in asymptomatic patients with Crohn’s disease. Scott Med J. 1983;28(1):26–9.

    CAS  PubMed  Google Scholar 

  16. Campbell CA, Walker-Smith JA, Hindocha P, Adinolfi M. Acute phase proteins in chronic inflammatory bowel disease in childhood. J Pediatr Gastroenterol Nutr. 1982;1(2):193–200.

    Article  CAS  PubMed  Google Scholar 

  17. Boirivant M, Leoni M, Tariciotti D, Fais S, Squarcia O, Pallone F. The clinical significance of serum C reactive protein levels in Crohn’s disease. Results of a prospective longitudinal study. J Clin Gastroenterol. 1988;10(4):401–5.

    Article  CAS  PubMed  Google Scholar 

  18. Harvey RF, Bradshaw JM. A simple index of Crohn’s-disease activity. Lancet. 1980;1(8167):514.

    Article  CAS  PubMed  Google Scholar 

  19. Bitton A, Dobkin PL, Edwardes MD, Sewitch MJ, Meddings JB, Rawal S, et al. Predicting relapse in Crohn’s disease: a biopsychosocial model. Gut. 2008;57(10):1386–92.

    Article  CAS  PubMed  Google Scholar 

  20. Koelewijn CL, Schwartz MP, Samsom M, Oldenburg B. C-reactive protein levels during a relapse of Crohn’s disease are associated with the clinical course of the disease. World J Gastroenterol. 2008;14(1):85–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  21. Wright JP, Young GO, Tigler-Wybrandi N. Predictors of acute relapse of Crohn’s disease. A laboratory and clinical study. Dig Dis Sci. 1987;32(2):164–70.

    Article  CAS  PubMed  Google Scholar 

  22. Kiss LS, Papp M, Lovasz BD, Vegh Z, Golovics PA, Janka E, et al. High-sensitivity C-reactive protein for identification of disease phenotype, active disease, and clinical relapses in Crohn’s disease: a marker for patient classification? Inflamm Bowel Dis. 2012;18(9):1647–54.

    Article  PubMed  Google Scholar 

  23. Vermeire S, Schreiber S, Sandborn WJ, Dubois C, Rutgeerts P. Correlation between the Crohn’s disease activity and Harvey–Bradshaw indices in assessing Crohn’s disease severity. Clin Gastroenterol Hepatol. 2010;8(4):357–63.

  24. Van Assche G, Dignass A, Panes J, Beaugerie L, Karagiannis J, Allez M, et al. The Second European Evidence-Based Consensus on the Diagnosis and Management of Crohn’s Disease: definitions and diagnosis. J Crohns Colitis. 2010;4(1):7–27.

  25. Jurgens M, Mahachie John JM, Cleynen I, Schnitzler F, Fidder H, van Moerkercke W, et al. Levels of C-reactive protein are associated with response to infliximab therapy in patients with Crohn’s disease. Clin Gastroenterol Hepatol. 2011;9(5):421–7.e1.

  26. Park JJ, Cheon JH, Hong SP, Kim TI, Kim WH. Outcome predictors for thiopurine maintenance therapy in patients with Crohn’s disease. Dig Dis Sci. 2012;57(1):133–41.

    Article  CAS  PubMed  Google Scholar 

  27. Kennedy NA, Kalla R, Warner B, Gambles CJ, Musy R, Reynolds S, et al. Thiopurine withdrawal during sustained clinical remission in inflammatory bowel disease: relapse and recapture rates, with predictive factors in 237 patients. Aliment Pharmacol Ther. 2014;40(11–12):1313–23.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  28. Brignola C, Campieri M, Bazzocchi G, Farruggia P, Tragnone A, Lanfranchi GA. A laboratory index for predicting relapse in asymptomatic patients with Crohn’s disease. Gastroenterology. 1986;91(6):1490–4.

    CAS  PubMed  Google Scholar 

  29. Consigny Y, Modigliani R, Colombel JF, Dupas JL, Lemann M, Mary JY, et al. A simple biological score for predicting low risk of short-term relapse in Crohn’s disease. Inflamm Bowel Dis. 2006;12(7):551–7.

    Article  PubMed  Google Scholar 

  30. Modigliani R, Colombel JF, Dupas JL, Dapoigny M, Costil V, Veyrac M, et al. Mesalamine in Crohn’s disease with steroid-induced remission: effect on steroid withdrawal and remission maintenance, Groupe d’Etudes Therapeutiques des Affections Inflammatoires Digestives. Gastroenterology. 1996;110(3):688–93 (Epub 1996/03/01).

    Article  CAS  PubMed  Google Scholar 

  31. Arias MT, Vande Casteele N, Vermeire S, de Buck van Overstraeten A, Billiet T, Baert F, et al. A panel to predict long-term outcome of infliximab therapy for patients with ulcerative colitis. Clin Gastroenterol Hepatol. 2015;13(3):531–8.

    Article  PubMed  Google Scholar 

  32. Leukert N, Vogl T, Strupat K, Reichelt R, Sorg C, Roth J. Calcium-dependent tetramer formation of S100A8 and S100A9 is essential for biological activity. J Mol Biol. 2006;359(4):961–72.

    Article  CAS  PubMed  Google Scholar 

  33. Propper C, Huang X, Roth J, Sorg C, Nacken W. Analysis of the MRP8-MRP14 protein–protein interaction by the two-hybrid system suggests a prominent role of the C-terminal domain of S100 proteins in dimer formation. J Biol Chem. 1999;274(1):183–8.

  34. Roseth AG, Fagerhol MK, Aadland E, Schjonsby H. Assessment of the neutrophil dominating protein calprotectin in feces. A methodologic study. Scand J Gastroenterol. 1992;27(9):793–8.

    Article  CAS  PubMed  Google Scholar 

  35. Tibble J, Teahon K, Thjodleifsson B, Roseth A, Sigthorsson G, Bridger S, et al. A simple method for assessing intestinal inflammation in Crohn’s disease. Gut. 2000;47(4):506–13.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  36. Tibble JA, Sigthorsson G, Bridger S, Fagerhol MK, Bjarnason I. Surrogate markers of intestinal inflammation are predictive of relapse in patients with inflammatory bowel disease. Gastroenterology. 2000;119(1):15–22.

    Article  CAS  PubMed  Google Scholar 

  37. Costa F, Mumolo MG, Ceccarelli L, Bellini M, Romano MR, Sterpi C, et al. Calprotectin is a stronger predictive marker of relapse in ulcerative colitis than in Crohn’s disease. Gut. 2005;54(3):364–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  38. Gerasimidis K, Nikolaou CK, Edwards CA, McGrogan P. Serial fecal calprotectin changes in children with Crohn’s disease on treatment with exclusive enteral nutrition: associations with disease activity, treatment response, and prediction of a clinical relapse. J Clin Gastroenterol. 2011;45(3):234–9.

    Article  PubMed  Google Scholar 

  39. Sipponen T, Kolho KL. Faecal calprotectin in children with clinically quiescent inflammatory bowel disease. Scand J Gastroenterol. 2010;45(7–8):872–7.

    Article  CAS  PubMed  Google Scholar 

  40. Kallel L, Ayadi I, Matri S, Fekih M, Mahmoud NB, Feki M, et al. Fecal calprotectin is a predictive marker of relapse in Crohn’s disease involving the colon: a prospective study. Eur J Gastroenterol Hepatol. 2010;22(3):340–5.

    Article  CAS  PubMed  Google Scholar 

  41. von Roon AC, Karamountzos L, Purkayastha S, Reese GE, Darzi AW, Teare JP, et al. Diagnostic precision of fecal calprotectin for inflammatory bowel disease and colorectal malignancy. Am J Gastroenterol. 2007;102(4):803–13.

    Article  Google Scholar 

  42. Johne B, Kronborg O, Ton HI, Kristinsson J, Fuglerud P. A new fecal calprotectin test for colorectal neoplasia. Clinical results and comparison with previous method. Scand J Gastroenterol. 2001;36(3):291–6.

    Article  CAS  PubMed  Google Scholar 

  43. Walkiewicz D, Werlin SL, Fish D, Scanlon M, Hanaway P, Kugathasan S. Fecal calprotectin is useful in predicting disease relapse in pediatric inflammatory bowel disease. Inflamm Bowel Dis. 2008;14(5):669–73.

    Article  PubMed  Google Scholar 

  44. Wassell J, Dolwani S, Metzner M, Losty H, Hawthorne A. Faecal calprotectin: a new marker for Crohn’s disease? Ann Clin Biochem. 2004;41(Pt 3):230–2.

    Article  CAS  PubMed  Google Scholar 

  45. Diamanti A, Colistro F, Basso MS, Papadatou B, Francalanci P, Bracci F, et al. Clinical role of calprotectin assay in determining histological relapses in children affected by inflammatory bowel diseases. Inflamm Bowel Dis. 2008;14(9):1229–35.

    Article  CAS  PubMed  Google Scholar 

  46. Naismith GD, Smith LA, Barry SJ, Munro JI, Laird S, Rankin K, et al. A prospective evaluation of the predictive value of faecal calprotectin in quiescent Crohn’s disease. J Crohns Colitis. 2014;8(9):1022–9.

    Article  PubMed  Google Scholar 

  47. Gisbert JP, Bermejo F, Perez-Calle JL, Taxonera C, Vera I, McNicholl AG, et al. Fecal calprotectin and lactoferrin for the prediction of inflammatory bowel disease relapse. Inflamm Bowel Dis. 2009;15(8):1190–8.

    Article  PubMed  Google Scholar 

  48. Garcia-Sanchez V, Iglesias-Flores E, Gonzalez R, Gisbert JP, Gallardo-Valverde JM, Gonzalez-Galilea A, et al. Does fecal calprotectin predict relapse in patients with Crohn’s disease and ulcerative colitis? J Crohns Colitis. 2010;4(2):144–52.

    Article  PubMed  Google Scholar 

  49. De Vos M, Louis EJ, Jahnsen J, Vandervoort JG, Noman M, Dewit O, et al. Consecutive fecal calprotectin measurements to predict relapse in patients with ulcerative colitis receiving infliximab maintenance therapy. Inflamm Bowel Dis. 2013;19(10):2111–7.

    Article  PubMed  Google Scholar 

  50. Molander P, Farkkila M, Ristimaki A, Salminen K, Kemppainen H, Blomster T, et al. Does fecal calprotectin predict short-term relapse after stopping TNFα-blocking agents in inflammatory bowel disease patients in deep remission? J Crohns Colitis. 2015;9(1):33–40.

  51. Naismith GD, Smith LA, Barry SJ, Munro JI, Laird S, Rankin K, et al. A prospective single-centre evaluation of the intra-individual variability of faecal calprotectin in quiescent Crohn’s disease. Aliment Pharmacol Ther. 2013;37(6):613–21.

    Article  CAS  PubMed  Google Scholar 

  52. Moum B, Jahnsen J, Bernklev T. Fecal calprotectin variability in Crohn’s disease. Inflamm Bowel Dis. 2010;16(7):1091–2.

    Article  PubMed  Google Scholar 

  53. Lasson A, Stotzer PO, Ohman L, Isaksson S, Sapnara M, Strid H. The intra-individual variability of faecal calprotectin: a prospective study in patients with active ulcerative colitis. J Crohns Colitis. 2015;9(1):26–32.

    PubMed  Google Scholar 

  54. Calafat M, Cabre E, Manosa M, Lobaton T, Marin L, Domenech E. High within-day variability of fecal calprotectin levels in patients with active ulcerative colitis: what is the best timing for stool sampling? Inflamm Bowel Dis. 2015;21(5):1072–6.

    Article  PubMed  Google Scholar 

  55. Sipponen T, Haapamaki J, Savilahti E, Alfthan H, Hamalainen E, Rautiainen H, et al. Fecal calprotectin and S100A12 have low utility in prediction of small bowel Crohn’s disease detected by wireless capsule endoscopy. Scand J Gastroenterol. 2012;47(7):778–84.

    Article  CAS  PubMed  Google Scholar 

  56. Gecse KB, Brandse JF, van Wilpe S, Lowenberg M, Ponsioen C, van den Brink G, et al. Impact of disease location on fecal calprotectin levels in Crohn’s disease. Scand J Gastroenterol. 2015;50(7):841–7.

    Article  CAS  PubMed  Google Scholar 

  57. Shaoul R, Sladek M, Turner D, Paeregaard A, Veres G, Wauters GV, et al. Limitations of fecal calprotectin at diagnosis in untreated pediatric Crohn’s disease. Inflamm Bowel Dis. 2012;18(8):1493–7.

    Article  PubMed  Google Scholar 

  58. Chang S, Malter L, Hudesman D. Disease monitoring in inflammatory bowel disease. World J Gastroenterol. 2015;21(40):11246–59.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  59. Laharie D, Mesli S, El Hajbi F, Chabrun E, Chanteloup E, Capdepont M, et al. Prediction of Crohn’s disease relapse with faecal calprotectin in infliximab responders: a prospective study. Aliment Pharmacol Ther. 2011;34(4):462–9.

    Article  CAS  PubMed  Google Scholar 

  60. Louis E, Mary JY, Vernier-Massouille G, Grimaud JC, Bouhnik Y, Laharie D, et al. Maintenance of remission among patients with Crohn’s disease on antimetabolite therapy after infliximab therapy is stopped. Gastroenterology. 2012;142(1):63–70.e5 (quiz e31).

  61. Leach ST, Yang Z, Messina I, Song C, Geczy CL, Cunningham AM, et al. Serum and mucosal S100 proteins, calprotectin (S100A8/S100A9) and S100A12, are elevated at diagnosis in children with inflammatory bowel disease. Scand J Gastroenterol. 2007;42(11):1321–31.

    Article  CAS  PubMed  Google Scholar 

  62. Malickova K, Janatkova I, Bortlik M, Komarek V, Lukas M. Calprotectin levels in patients with idiopathic inflammatory bowel disease comparison of two commercial tests (Stanoveni koncentrace kalprotektinu ve stolici u nemocnych s idiopatickymi strevnimi zanety-srovnani dvou komercnich testu). Epidemiol Mikrobiol Imunol. 2008;57(4):147–53.

    CAS  PubMed  Google Scholar 

  63. Meuwis MA, Vernier-Massouille G, Grimaud JC, Bouhnik Y, Laharie D, Piver E, et al. Serum calprotectin as a biomarker for Crohn’s disease. J Crohns Colitis. 2013;7(12):e678–83.

    Article  PubMed  Google Scholar 

  64. Orlando A, Modesto I, Castiglione F, Scala L, Scimeca D, Rispo A, et al. The role of calprotectin in predicting endoscopic post-surgical recurrence in asymptomatic Crohn’s disease: a comparison with ultrasound. Eur Rev Med Pharmacol Sci. 2006;10(1):17–22.

    CAS  PubMed  Google Scholar 

  65. Lasson A, Strid H, Ohman L, Isaksson S, Olsson M, Rydstrom B, et al. Fecal calprotectin one year after ileocaecal resection for Crohn’s disease—a comparison with findings at ileocolonoscopy. J Crohns Colitis. 2014;8(8):789–95.

    Article  PubMed  Google Scholar 

  66. Sipponen T, Savilahti E, Kolho KL, Nuutinen H, Turunen U, Farkkila M. Crohn’s disease activity assessed by fecal calprotectin and lactoferrin: correlation with Crohn’s disease activity index and endoscopic findings. Inflamm Bowel Dis. 2008;14(1):40–6.

    Article  PubMed  Google Scholar 

  67. D’Haens G, Ferrante M, Vermeire S, Baert F, Noman M, Moortgat L, et al. Fecal calprotectin is a surrogate marker for endoscopic lesions in inflammatory bowel disease. Inflamm Bowel Dis. 2012;18(12):2218–24.

    Article  PubMed  Google Scholar 

  68. Wright EK, Kamm MA, De Cruz P, Hamilton AL, Ritchie KJ, Krejany EO, et al. Measurement of fecal calprotectin improves monitoring and detection of recurrence of Crohn’s disease after surgery. Gastroenterology. 2015;148(5):938–47 e1.

  69. Boschetti G, Laidet M, Moussata D, Stefanescu C, Roblin X, Phelip G, et al. Levels of fecal calprotectin are associated with the severity of postoperative endoscopic recurrence in asymptomatic patients with Crohn’s disease. Am J Gastroenterol. 2015;110(6):865–72.

    Article  CAS  PubMed  Google Scholar 

  70. Gisbert JP, Gonzalez-Lama Y, Mate J. Role of biological markers in inflammatory bowel disease (Papel de los marcadores biologicos en la enfermedad inflamatoria intestinal). Gastroenterol Hepatol. 2007;30(3):117–29.

    Article  PubMed  Google Scholar 

  71. Baveye S, Elass E, Mazurier J, Spik G, Legrand D. Lactoferrin: a multifunctional glycoprotein involved in the modulation of the inflammatory process. Clin Chem Lab Med. 1999;37(3):281–6.

    Article  CAS  PubMed  Google Scholar 

  72. Angriman I, Scarpa M, D’Inca R, Basso D, Ruffolo C, Polese L, et al. Enzymes in feces: useful markers of chronic inflammatory bowel disease. Clin Chim Acta. 2007;381(1):63–8.

    Article  CAS  PubMed  Google Scholar 

  73. Guerrant RL, Araujo V, Soares E, Kotloff K, Lima AA, Cooper WH, et al. Measurement of fecal lactoferrin as a marker of fecal leukocytes. J Clin Microbiol. 1992;30(5):1238–42.

    CAS  PubMed  PubMed Central  Google Scholar 

  74. Sugi K, Saitoh O, Hirata I, Katsu K. Fecal lactoferrin as a marker for disease activity in inflammatory bowel disease: comparison with other neutrophil-derived proteins. Am J Gastroenterol. 1996;91(5):927–34.

    CAS  PubMed  Google Scholar 

  75. Silberer H, Kuppers B, Mickisch O, Baniewicz W, Drescher M, Traber L, et al. Fecal leukocyte proteins in inflammatory bowel disease and irritable bowel syndrome. Clin Lab. 2005;51(3–4):117–26.

    CAS  PubMed  Google Scholar 

  76. Gisbert JP, McNicholl AG, Gomollon F. Questions and answers on the role of fecal lactoferrin as a biological marker in inflammatory bowel disease. Inflamm Bowel Dis. 2009;15(11):1746–54.

    Article  PubMed  Google Scholar 

  77. Dabritz J, Musci J, Foell D. Diagnostic utility of faecal biomarkers in patients with irritable bowel syndrome. World J Gastroenterol. 2014;20(2):363–75.

    Article  PubMed  PubMed Central  Google Scholar 

  78. Lamb CA, Mohiuddin MK, Gicquel J, Neely D, Bergin FG, Hanson JM, et al. Faecal calprotectin or lactoferrin can identify postoperative recurrence in Crohn’s disease. Br J Surg. 2009;96(6):663–74.

    Article  CAS  PubMed  Google Scholar 

  79. Yamamoto T, Shiraki M, Bamba T, Umegae S, Matsumoto K. Faecal calprotectin and lactoferrin as markers for monitoring disease activity and predicting clinical recurrence in patients with Crohn’s disease after ileocolonic resection: a prospective pilot study. United Eur Gastroenterol J. 2013;1(5):368–74.

    Article  Google Scholar 

  80. Buderus S, Boone J, Lyerly D, Lentze MJ. Fecal lactoferrin: a new parameter to monitor infliximab therapy. Dig Dis Sci. 2004;49(6):1036–9.

    Article  CAS  PubMed  Google Scholar 

  81. Truelove SC, Witts LJ. Cortisone in ulcerative colitis; final report on a therapeutic trial. Br Med J. 1955;2(4947):1041–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  82. Yamamoto T, Shiraki M, Bamba T, Umegae S, Matsumoto K. Fecal calprotectin and lactoferrin as predictors of relapse in patients with quiescent ulcerative colitis during maintenance therapy. Int J Colorectal Dis. 2014;29(4):485–91.

    Article  PubMed  Google Scholar 

  83. Turner D, Leach ST, Mack D, Uusoue K, McLernon R, Hyams J, et al. Faecal calprotectin, lactoferrin, M2-pyruvate kinase and S100A12 in severe ulcerative colitis: a prospective multicentre comparison of predicting outcomes and monitoring response. Gut. 2010;59(9):1207–12.

    Article  CAS  PubMed  Google Scholar 

  84. Walker TR, Land ML, Kartashov A, Saslowsky TM, Lyerly DM, Boone JH, et al. Fecal lactoferrin is a sensitive and specific marker of disease activity in children and young adults with inflammatory bowel disease. J Pediatr Gastroenterol Nutr. 2007;44(4):414–22.

    Article  CAS  PubMed  Google Scholar 

  85. Dabritz J, Langhorst J, Lugering A, Heidemann J, Mohr M, Wittkowski H, et al. Improving relapse prediction in inflammatory bowel disease by neutrophil-derived S100A12. Inflamm Bowel Dis. 2013;19(6):1130–8.

    Article  PubMed  Google Scholar 

  86. Foell D, Wittkowski H, Kessel C, Luken A, Weinhage T, Varga G, et al. Proinflammatory S100A12 can activate human monocytes via Toll-like receptor 4. Am J Respir Crit Care Med. 2013;187(12):1324–34 (Epub 2013/04/25).

  87. Manolakis AC, Kapsoritakis AN, Tiaka EK, Potamianos SP. Calprotectin, calgranulin C, and other members of the s100 protein family in inflammatory bowel disease. Dig Dis Sci. 2011;56(6):1601–11 (Epub 2011/01/05).

    Article  CAS  PubMed  Google Scholar 

  88. Sidler MA, Leach ST, Day AS. Fecal S100A12 and fecal calprotectin as noninvasive markers for inflammatory bowel disease in children. Inflamm Bowel Dis. 2008;14:359–66.

    Article  PubMed  Google Scholar 

  89. Meyers S, Wolke A, Field SP, Feuer EJ, Johnson JW, Janowitz HD. Fecal α1-antitrypsin measurement: an indicator of Crohn’s disease activity. Gastroenterology. 1985;89:13–8.

    CAS  PubMed  Google Scholar 

  90. Boirivant M, Pallone F, Ciaco A, Leoni M, Fais S, Torsoli A. Usefulness of fecal alpha 1-antitrypsin clearance and fecal concentration as early indicator of postoperative asymptomatic recurrence in Crohn’s disease. Dig Dis Sci. 1991;36(3):347–52.

    Article  CAS  PubMed  Google Scholar 

  91. Biancone L, Fantini M, Tosti C, Bozzi R, Vavassori P, Pallone F. Fecal alpha 1-antitrypsin clearance as a marker of clinical relapse in patients with Crohn’s disease of the distal ileum. Eur J Gastroenterol Hepatol. 2003;15(3):261–6.

    Article  CAS  PubMed  Google Scholar 

  92. Saitoh O, Kojima K, Sugi K, Matsuse R, Uchida K, Tabata K, et al. Fecal eosinophil granule-derived proteins reflect disease activity in inflammatory bowel disease. Am J Gastroenterol. 1999;94(12):3513–20.

    Article  CAS  PubMed  Google Scholar 

  93. Egea L, Hirata Y, Kagnoff MF. GM-CSF: a role in immune and inflammatory reactions in the intestine. Expert Rev Gastroenterol Hepatol. 2010;4(6):723–31.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  94. Guthridge MA, Powell JA, Barry EF, Stomski FC, McClure BJ, Ramshaw H, et al. Growth factor pleiotropy is controlled by a receptor Tyr/Ser motif that acts as a binary switch. EMBO J. 2006;25(3):479–89.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  95. Bernasconi E, Favre L, Maillard MH, Bachmann D, Pythoud C, Bouzourene H, et al. Granulocyte-macrophage colony-stimulating factor elicits bone marrow-derived cells that promote efficient colonic mucosal healing. Inflamm Bowel Dis. 2010;16:428–41.

    Article  PubMed  Google Scholar 

  96. Dabritz J. Granulocyte macrophage colony-stimulating factor and the intestinal innate immune cell homeostasis in Crohn’s disease. Am J Physiol Gastrointest Liver Physiol. 2014;306(6):G455–65.

    Article  CAS  PubMed  Google Scholar 

  97. Dabritz J, Bonkowski E, Chalk C, Trapnell BC, Langhorst J, Denson LA, et al. Granulocyte macrophage colony-stimulating factor auto-antibodies and disease relapse in inflammatory bowel disease. Am J Gastroenterol. 2013;108(12):1901–10.

    Article  PubMed  Google Scholar 

  98. Amre DK, Lu SE, Costea F, Seidman EG. Utility of serological markers in predicting the early occurrence of complications and surgery in pediatric Crohn’s disease patients. Am J Gastroenterol. 2006;101(3):645–52.

    Article  PubMed  Google Scholar 

  99. Lakatos PL, Kiss LS, Palatka K, Altorjay I, Antal-Szalmas P, Palyu E, et al. Serum lipopolysaccharide-binding protein and soluble CD14 are markers of disease activity in patients with Crohn’s disease. Inflamm Bowel Dis. 2011;17(3):767–77.

    Article  PubMed  Google Scholar 

  100. Wagner M, Peterson CG, Ridefelt P, Sangfelt P, Carlson M. Fecal markers of inflammation used as surrogate markers for treatment outcome in relapsing inflammatory bowel disease. World J Gastroenterol. 2008;14(36):5584–9 (discussion 8).

    Article  PubMed  PubMed Central  Google Scholar 

  101. Louis E, Belaiche J, Van Kemseke C, Schaaf N, Mahieu P, Mary JY. Soluble interleukin-2 receptor in Crohn’s disease. Assessment of disease activity and prediction of relapse. Dig Dis Sci. 1995;40(8):1750–6.

    Article  CAS  PubMed  Google Scholar 

  102. Louis E, Belaiche J, van Kemseke C, Franchimont D, de Groote D, Gueenen V, et al. A high serum concentration of interleukin-6 is predictive of relapse in quiescent Crohn’s disease. Eur J Gastroenterol Hepatol. 1997;9(10):939–44.

    Article  CAS  PubMed  Google Scholar 

  103. D'Incà R, Dal Pont E, Di Leo V, Benazzato L, Martinato M, Lamboglia F, et al. Can calprotectin predict relapse risk in inflammatory bowel disease? Am J Gastroenterol. 2008;103(8):2007–14.

    Article  PubMed  Google Scholar 

  104. Guardiola J, Lobatón T, Rodríguez-Alonso L, Ruiz-Cerulla A, Arajol C, Loayza C, et al. Fecal level of calprotectin identifies histologic inflammation in patients with ulcerative colitis in clinical and endoscopic remission. Clin Gastroenterol Hepatol. 2014;12(11):1865–70. doi:10.1016/j.cgh.2014.06.020.

    Article  CAS  PubMed  Google Scholar 

  105. Walkiewicz D, Werlin SL, Fish D, Scanlon M, Hanaway P, Kugathasan S. Fecal calprotectin is useful in predicting disease relapse in pediatric inflammatory bowel disease. Inflamm Bowel Dis. 2008;14(5):669–73. doi:10.1002/ibd.20376.

    Article  PubMed  Google Scholar 

  106. Casellas F, Borruel N, Antolín M, Varela E, Torrejón A, Armadans L, et al. Fecal excretion of deoxyribonucleic acid in long-term follow-up of patients with inactive ulcerative colitis. Inflamm Bowel Dis. 2007;13(4):386–90.

    Article  PubMed  Google Scholar 

  107. Braegger CP, Nicholls S, Murch SH, Stephens S, MacDonald TT. Tumour necrosis factor alpha in stool as a marker of intestinal inflammation. Lancet. 1992;339(8785):89–91.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Author notes

    Authors and Affiliations

    1. Intensive Care Department, Austin Hospital, Heidelberg, VIC, 3084, Australia

      Jason Orlando Dimitri Musci

    2. School of Medicine, Deakin University, Geelong, VIC, 3220, Australia

      Jack Stephen Cornish

    3. Department of Paediatrics, University Children’s Hospital Rostock, Ernst-Heydemann-Str. 8, 18057, Rostock, Germany

      Jan Däbritz

    Authors
    1. Jason Orlando Dimitri Musci
      View author publications

      You can also search for this author in PubMed Google Scholar

    2. Jack Stephen Cornish
      View author publications

      You can also search for this author in PubMed Google Scholar

    3. Jan Däbritz
      View author publications

      You can also search for this author in PubMed Google Scholar

    Corresponding author

    Correspondence to Jan Däbritz.

    Ethics declarations

    Conflict of interest

    The authors declare that they have no conflict of interest.

    Source of funding

    No financial support.

    Additional information

    J. O. D. Musci and J. S. Cornish contributed equally to this work.

    Rights and permissions

    Reprints and permissions

    About this article

    Check for updates. Verify currency and authenticity via CrossMark

    Cite this article

    Musci, J.O.D., Cornish, J.S. & Däbritz, J. Utility of surrogate markers for the prediction of relapses in inflammatory bowel diseases. J Gastroenterol 51, 531–547 (2016). https://doi.org/10.1007/s00535-016-1191-3

    Download citation

    • Received:

    • Accepted:

    • Published:

    • Issue Date:

    • DOI: https://doi.org/10.1007/s00535-016-1191-3

    Keywords

    Search

    Navigation